• Hansa Biopharma submitted an investigational new drug application to the FDA for HNSA-5487 in Guillain-Barré syndrome.
• Subject to FDA review, a small Phase 2a single ascending dose study is planned, followed by a pivotal study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansa Biopharma AB published the original content used to generate this news brief via Cision (Ref. ID: 202610201105BITN____UKPR__EN_20261020-BIT-7088-0) on October 20, 2026, and is solely responsible for the information contained therein.